Furthermore, triple-negative breast cancer emerges as an ideal target for ferroptosis induction therapy due to unique metabolic traits: aberrant PUFA accumulation, elevated labile iron pool, and impaired GPX4-GSH defense [227]. This evidence concerns the gene GPX4 and triple-negative breast carcinoma.